Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxypurinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH known ✓ | P47989 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359458 | 0.75 | PARP1 (0.55) | KDM4EALDH1A1MAPTCYP1A2HSD17B10 | |
| Oxypurinol SCHEMBL8258318 | 0.67 | KDM4E (0.31) | KDM4EKMT2A | |
| SCHEMBL30472927 | 0.66 | ADORA2B (0.46) | KDM4EALDH1A1MAPTGAABLM | |
| SCHEMBL20272419 | 0.65 | KDM4E (0.39) | GDAXDHACHEKDM4EALDH1A1 | |
| SCHEMBL29406967 | 0.64 | PARP1 (0.67) | KDM4EALDH1A1MAPTBLMTDP1 | |
| SCHEMBL1441934 | 0.64 | PARP1 (0.67) | KDM4EALDH1A1MAPTBLMTDP1 | |
| SCHEMBL30032670 | 0.64 | GDA (0.41) | GDAXDHACHEKDM4EALDH1A1 | |
| SCHEMBL3726392 | 0.64 | GDA (0.41) | GDAXDHACHEKDM4EALDH1A1 | |
| SCHEMBL15798530 | 0.64 | KDM4E (0.39) | GDAXDHACHEKDM4EALDH1A1 | |
| SCHEMBL1218582 | 0.63 | GRIN2D (0.49) | XDHKDM4EALDH1A1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240028-B1 | Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical | INTRA CELLULAR THERAPIES INC (US) | 2016-07-20 | — | — | EP | claimed |
| EP-2023729-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-05-04 | — | — | EP | claimed |
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | claimed |
| US-8846693-B2 | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-09-30 | — | — | US | claimed |
| EP-2575817-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2011153136-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2011-12-08 | — | — | WO | claimed |
| US-20100273753-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | claimed |
| US-20100173878-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-07-08 | — | — | US | claimed |
| EP-0975636-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-02-02 | — | — | EP | claimed |
| WO-1998046606-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-22 | — | — | WO | claimed |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-112166110-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2021-01-01 | — | — | CN | disclosed |
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | EFFECTOR THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9487527-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9434730-B2 | PDE1 inhibitor compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-0383465-A2 | Tricyclic fused pyrimidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-08-22 | — | — | EP | disclosed |
| US-4511557-A | CALF'S BLOOD DIAYSATE AS VASODILATION POTENTIATOR | GAURI KAILASH KUMAR (DE) | 1985-04-16 | — | — | US | disclosed |
| EP-0077372-A1 | NEW DERIVATIVES OF PYRAZOLO(3,4-d)PYRIMIDINE, PREPARATION METHOD THEREOF AND REMEDY CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-04-27 | — | — | EP | disclosed |
| WO-1982003626-A1 | NEW DERIVATIVES OF PYRAZOLO(3,4-D)PYRIMIDINE,PREPARATION METHOD THEREOF AND REMEDY CONTAINING THEM | GAURI KAILASH KUMAR | 1982-10-28 | — | — | WO | disclosed |
| EP-0063381-A1 | Pyrazolo(3-4-d) pyrimidines, process for their preparation and pharmaceutical compositions containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273753-A1 | ORGANIC COMPOUNDS | OPRD1, PGR, HTR1D | XDH 188/4885GDA 1914/4885ACHE 659/4885 |
| US-20100173878-A1 | ORGANIC COMPOUNDS | PDE3A, PDE7A, PDE3B | XDH 96/4885GDA 238/4885ACHE 139/4885 |
| US-20150197524-A1 | ORGANIC COMPOUNDS | OPRD1, HTR1D, DRD1 | XDH 181/4885GDA 1854/4885ACHE 607/4885 |
| US-10000487-B2 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | MAP3K9, MAP3K19, MAP3K20 | XDH 3031/4885GDA 4559/4885ACHE 1576/4885 |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | PDE12, PDE5A, PDE3A | XDH 697/4885GDA 195/4885ACHE 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.